Moira L Aitken, | |
University Of Washington Medical Ctr, 1959 Ne Pacific St, Seattle, WA 98195-6166 | |
(206) 598-4615 | |
Not Available |
Full Name | Moira L Aitken |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | University Of Washington Medical Ctr, Seattle, Washington |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1558446385 | NPI | - | NPPES |
290004639 | Other | WA | RAILROAD MEDICARE |
1014463 | Medicaid | WA | |
6000 | Other | INTERNAL ID-MOTOR VEHICLE ID |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RP1001X | Internal Medicine - Pulmonary Disease | MD00020520 (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
Moira L Aitken, Po Box 50095, Seattle, WA 98145-5095 Ph: () - | Moira L Aitken, University Of Washington Medical Ctr, 1959 Ne Pacific St, Seattle, WA 98195-6166 Ph: (206) 598-4615 |
News Archive
Scientists at The Scripps Research Institute (TSRI) have found that even brief workouts can reduce the risk of relapse in rats withdrawing from methamphetamine. In addition, the team found that exercise affected the neurons in a brain region that had never before been associated with meth withdrawal, suggesting a new direction for drug development.
As doctors and hospitals begin to transition to electronic medical records, one industry obstacle remains: ensuring that patients' records can smoothly follow them from one provider to another, the Associated Press reports. Though new stimulus funding for electronic records requires records to be "interoperable," or shareable, "the debate over interoperability among health care providers, which has been going on for years, could take well beyond the 2014 timeframe to be solved, industry experts say."
Columbia University Medical Center (CUMC) scientists have identified new genetic mutations that can cause pulmonary arterial hypertension (PAH), a rare fatal disease characterized by high blood pressure in the lungs.
Gilead Sciences, Inc. today announced that it has dosed the first patient in the Phase III clinical program evaluating its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat (formerly GS 9350), emtricitabine and tenofovir disoproxil fumarate.
› Verified 7 days ago
Sandhya Ramanathan Panch, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5000 | |
Stephen A Lopez, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 925 Seneca St, Seattle, WA 98101 Phone: 206-341-0860 | |
Dr. Susan Hunt, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: Uwmc Department Of Medicine, Box 356429, Seattle, WA 98195 Phone: 206-221-7993 Fax: 206-221-8732 | |
Timothy William Menza, MD, PHD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-520-5000 | |
Dr. Vinay Gupta, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1100 9th Ave, Seattle, WA 98101 Phone: 206-223-6980 Fax: 206-223-6982 | |
Dr. Maria Ann Corcorran, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1550 N 115th St, Seattle, WA 98133 Phone: 206-520-5000 | |
Vyshak Alva Venur, M.D Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5700 |